Table 3. Univariate and multivariate analysis of PFS in patients with mCRC.

Characteristic	Univariate analysis				Multivariate analysis
	HR	95% CI	P		HR	95% CI	P
Age (year)
<63	1 (Ref)
≥63	0.887	0.482–1.631	0.699
Gender
Male	1 (Ref)
Female	0.673	0.354–1.279	0.226
Tumor localization
Colon	1 (Ref)
Rectum	0.907	0.492–1.674	0.756
Metastasis sites
Liver	1 (Ref)
Others	1.012	0.541–1.890	0.971
Chemotherapy regimens
FOLFORI	1 (Ref)
FOLFOX	0.993	0.479–2.060	0.986
XELOX	0.941	0.420–2.108	0.882
PLR value
High PLR groupa	1 (Ref)				1 (Ref)
Low PLR groupb	0.513	0.276–0.954	0.035		0.643	0.336–1.231	0.183
NLR value
High NLR groupc	1 (Ref)				1 (Ref)
Low NLR groupd	0.423	0.223–0.803	0.008		0.503	0.257–0.981	0.044
CTC counts
CTC negative groupe	1 (Ref)				1 (Ref)
CTC positive groupf	2.155	1.152–4.032	0.016		1.925	1.008–3.676	0.047

^a, High PLR group, PLR ≥117.81; ^b, Low PLR group, PLR <117.81; ^c, High NLR group, NLR ≥2.02; ^d, Low NLR group, NLR <2.02; ^e, CTC negative group, CTCs count =0; ^f, CTC positive group, CTCs count ≥1. HR hazard ratio; CI confidence interval; Ref reference; PLR, platelet-lymphocyte ratio; NLR, neutrophil-lymphocyte ratio; CTCs, circulating tumor cells.